Topical treatment and combination approaches for vitiligo: New insights, new developments

Giornale Italiano di Dermatologia e Venereologia

Volumn 145, Issue 1, 2010, Pages 57-78

  Hossani Madani, A R ^a   Halder, R M ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Heliotherapy; Steroids; Tacrolimus; Vitiligo

Indexed keywords

BETAMETHASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; BETAMETHASONE VALERATE; CALCINEURIN INHIBITOR; CALCIPOTRIOL; CLOBETASOL PROPIONATE; CORTICOSTEROID; DERMATOLOGICAL AGENT; FLUOCINOLONE ACETONIDE; FLUTICASONE PROPIONATE; HYDROCORTISONE BUTYRATE; MEQUINOL; MONOBENZONE; PIMECROLIMUS; PLACEBO; PSEUDOCATALASE; TACALCITOL; TACROLIMUS; UNCLASSIFIED DRUG; VITAMIN D;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; EXCIMER LASER; HUMAN; MONOTHERAPY; PATHOGENESIS; PHOTOTHERAPY; PUNCH GRAFTING; PUVA; REVIEW; SKIN TRANSPLANTATION; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; VITILIGO;

EID: 77952388724     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Taieb A, Picardo M. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007;20:27-35. (Pubitemid 46090162)
2. Sehgal VN, Srivastava G. Vitiligo: compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol 2007;73:149-156
3. Nordlund JJ. The epidemiology and genetics of vitiligo. Clin Dermatol 1997;15:875-878
4. Lerner AB. Vitiligo. J Invest Dermatol 1959;32:285-310.
5. Bystryn JC. Immune mechanisms in vitiligo. Clin Dermatol 1997;15:853-861
6. Rezaei N, Gavalas NG, Weetman AP, Kemp EH. Autoimmunity as an aetiological factor in vitiligo. J Eur Acad Dermatol Venereol 2007;21:865-876
7. Njoo MD, Westerhof W. Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol 2001;2:167-181
8. Sprite RA. The genetics of generalized vitiligo and associated autoimmune diseases. J Dermatol Sci 2006;41:3-10.
9. Castanet J, Ortonne JP. Pathophysiology of vitiligo. Clin Dermatol 1997;15:845-851
10. Puri N, Mojamdar M, Ramaiah A. In vitro growth characteristics of melanocytes obtained from adult normal and vitiligo subjects. J Invest Dermatol 1987;88:434-438
11. Grimes PE, Sevall JS, Vojdani A. Cytomegalovirus DNA identified in skin biopsy specimens of patients with vitiligo. J Am Acad Dermatol 1996;35:21-26 (Pubitemid 26231317)
12. Le Poole IC, Das PK, van den Wijngaard RM, Bos JD, Westerhof W. Review of the etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol 1993;2:145-153 (Pubitemid 24009468)
13. Oyaibide-Valencia K, van den Boom JG, Denman CJ et al. Therapeutic implications of autoimmune vitiligo T cells. Autoimmun Rev 2006;5:486-492 (Pubitemid 44236282)
14. Khalid M, Mujtaba G, Haroon TS. Comparison of 0.05% clobetasol propionate cream and topical Puvasol in childhood vitiligo. Int J Dermatol 1995;34:203-205.
15. Lepe V, Moncada B, Castanedo-Cazares JP, Tones-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003;139:581-585 (Pubitemid 36576373)
16. Njoo MD, Spuls PI, Bos JD, Westerhof W, Bossuyt PM. Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature. Arch Dermatol 1998;134:1532-1540
17. Kandil E. Treatment of vitiligo with 0-1 per cent betamethasone 17-valerate in isopropyl alcohol - a double-blind trial. Br J Dermatol 1974;91:457-460
18. Clayton R. A double-blind trial of 0-05% clobetasol proprionate in the treatment of vitiligo. Br J Dermatol 1977;96:71-73 (Pubitemid 8072502)
19. Whitton ME, Ashcroft DM, Barrett CW, Gonzalez U. Interventions for vitiligo. Cochrane Database Syst Rev 2006;CDO03263.
20. Westerhof W, Nieuweboer-Krobotova L, Mulder PG, Glazenburg EJ. Left-right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for me long-term treatment of vitiligo. Arch Dermatol 1999;135:1061-1066 (Pubitemid 29430496)
21. Kumaran MS, Kaur I, Kumar B. Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol 2006;20:269-273
22. Sanclemente G, Garcia JJ, Zuleta JJ, Diehl C, Correa C, Falabella R. A double-blind, randomized trial of 0.05% betamethasone vs. topical catalase/dismutase superoxide in vitiligo. J Eur Acad Dermatol Venereol 2008;22:1359-1364
23. Kostovic K, Pasic A. New treatment modalities for vitiligo: focus on topical immunomodulators. Drugs 2005;65:447-459 (Pubitemid 40469551)
24. Boone B, Ongenae K, Van GN, Vernijns S, De KS, Naeyaert JM. Topical pimecrolimus in the treatment of vitiligo. Eur J Dermatol 2007;17:55-61.
25. Tjioe M, Vissers WH, Gerritsen MJ. Topical macrolide immunomodulators: a role in the treatment of vitiligo? Am J Clin Dermatol 2006;7:7-12.
26. Dawid M, Veensalu M, Grassberger M, Wolff K. Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized, double-blind, vehicle-controlled study. J Dtsch Dermatol Ges 2006;4:942-946 (Pubitemid 44671823)
27. Farajzadeh S, Daraei Z, Esfandiarpour I, Hosseini SH. The efficacy of pimecrolimus 1% cream combined with microdermabrasion in the treatment of nonsegmental childhood vitiligo: a randomized placebo-controlled study. Pediatr Dermatol 2009;26:286-291
28. Radakovic S, Breier-Maly J, Konschiteky R et al. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial. J Eur Acad Dermatol Venereol 2009;23:951-953
29. Schallreuter KU, Pittelkow MP. Defective calcium uptake in keratinocyte cell cultures from vitiliginous skin. Arch Dermatol Res 1988;280:137-139.
30. Schallreuter-Wood KU, Pittelkow MR, Swanson NN. Defective calcium transport in vitiliginous melanocytes. Arch Dermatol Res 1996;288:11-13
31. Schallreuter KU, Gibbons NC, Zothner C, Abou Elloof MM, Wood JM. Hydrogen peroxide-mediated oxidative stress disrupts calcium binding on calmodulin: more evidence for oxidative stress in vitiligo. Biochem Biophys Res Commun 2007;360:70-75 (Pubitemid 46992795)
32. Schallreuter KU, Moore J, Wood JM. Pseudocatalase in the Treatment of Vitiligo. Hann SK, Nordlund JJ, editors. Vitiligo: A Monograph on the Basic and Clinical Science 2000;182-192
33. Glaser R, Rowert J, Mrowietz U. Hyperpigmentation due to topical calcipotriol and photochemotherapy in two psoriatic patients. Br J Dermatol 1998;139:148-151 (Pubitemid 28338084)
34. Rutter A, Schwarz T. Marked hyperpigmentation in psoriatic plaque as a sequelae of combination therapy with UVB-311 and calcipotriol. Hautarzt 2000;51:431-433 (Pubitemid 30409381)
35. Chiaverini C, Passeron T, Ortonne JP. Treatment of vitiligo by topical calcipotriol. J Eur Acad Dermatol Venereol 2002;16:137-138 (Pubitemid 34460713)
36. Schallreuter KU, Wood JM, Lemke KR, Levenig C. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology 1995;190:223-229
37. Oettel H. Die Hydrochinonenvergiftung. Arch Exp Path Pharmakol 1936; 183:319-362
38. Oliver EA, Schwartz L, Warren LH. Occupational Leukoderma: Preliminary Report. JAMA 1939;113:927-928
39. Hariharan V, Klarquist J, Reust MJ et al. Monobenzy 1 ether of hydroquinone and 4-tertiary butyl phenol activate markedly different physiological responses in melanocytes: relevance to skin depigmentation. J Invest Dermatol 2010;130:211-220
40. Oakley AM. Rapid repigmentation after depigmentation therapy: vitiligo treated with monobenzyl ether of hydroquinone. Australas J Dermatol 1996;37:96-98
41. Mosher DB, Parrish JA, Fitzpatrick TB. Monobenzylether of hydroquinone. A retrospective study of treatment of 18 vitiligo patients and a review of the literature. Br J Dermatol 1977;97:669-679
42. Njoo MD, Vodegel RM, Westerhof W. Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and the Q-switched ruby laser. J Am Acad Dermatol 2000;42:760-769 (Pubitemid 30252879)
43. Sassi F, Cazzaniga S, Tessari G et al. Randomized controlled trial comparing the effectiveness of 308-nm excimer laser alone or in combination with topical hydrocortisone 17-butyrate cream in the treatment of vitiligo of the face and neck. Br J Dermatol 2008;159: 1186-91.
44. Barman KD, Khaitan BK, Verma KK. A comparative study of punch grafting followed by topical corticosteroid versus punch grafting followed by PUVA therapy in stable vitiligo. Dermatol Surg 2004;30:49-53.
45. Bakis-Petsoglou S, Le Guay JL, Wittal R. A randomized, double-blinded, placebo-controlled trial of pseudocatalase cream and narrowband ultraviolet B in the treatment of vitiligo. Br J Dermatol 2009;161:910-917
46. Rodriguez-Martin M, Garcia BM, Saez RM, Noda CA. Randomized, double-blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult nonsegmental vitiligo. Br J Dermatol 2009;160:409-414
47. Leone G, Pacifico A, Iacovelli P, Paro VA, Picardo M. Tacalcitol and narrow-band phototherapy in patients with vitiligo. Clin Exp Dermatol 2006;31:200-205
48. Lu-yan T, Wen-wen F, Lei-hong X, Yi J, Zhi-zhong Z. Topical tacalcitol and 308-nm monochromatic excimer light: a synergistic combination for the treatment of vitiligo. Photodermatol Photoimmunol Photomed 2006;22:310-314 (Pubitemid 44712308)
49. Arca E, Tastan HB, Erbil AH, Sezer E, Koc E, Kurumlu Z. Narrowband ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo. J Dermatol 2006;33:338-343 (Pubitemid 43943367)
50. Ermis O, Alpsoy E, Cetin L, Yilmaz E. Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study. Br J Dermatol 2001;145:472-475 (Pubitemid 32953706)
51. Parsad D, Saini R, Verma N. Combination of PUVAsol and topical calcipotriol in vitiligo. Dermatology 1998;197:167-170 (Pubitemid 28395846)
52. Goldinger SM, Dummer R, Schmid P, Burg G, Seifert B, Lauchli S. Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. J Eur Acad Dermatol Venereol 2007;21:504-508 (Pubitemid 46454904)
53. Kawalek AZ, Spencer JM, Phelps RG. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg 2004;30:130-135 (Pubitemid 38313998)
54. Passeron T, Ostovari N, Zakaria W, Fontas E, Larrouy JC, Lacour JP et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004;140:1065-1069 (Pubitemid 39223113)
55. Esfandiarpour I, Ekhlasi A, Farajzadeh S, Shamsadini S. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. J Dermatolog Treat 2009;20:14-18
56. Hui-Lan Y, Xiao-Yan H, Jian-Yong F, Zong-Rong L. Combination of 308-nm excimer laser with topical pimecrolimus for the treatment of childhood vitiligo. Pediatr Dermatol 2009;26:354-356